Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial
Authors' conclusion
Residual levels of anti-Xa activity do not reliably fall below 0.2 IU/mL 24 hours following discontinuation of treatment-dose enoxaparin.
Study context
- Population
- Patients on treatment-dose enoxaparin presenting for elective surgeryanalysed
- Participants
- 103 patients
- Exposure
- Last treatment dose of enoxaparin 24 hours vs 36 hours before surgery
- Outcome
- Residual anti-Xa level activity following the last treatment dose of enoxaparin
- Follow-up
- On arrival for surgery
Methodological detailsrandomised timing of last dose
- Randomised timing of last dose
Main finding
As reported in the abstract
Time from last dose at which residual anti-Xa activity fell below 0.2 IU/mL (linear regression, all patients; upper bound of 95% CI)
Time from last dose to anti-Xa <0.2 IU/mL, based on upper bound of 95% CI
31.5 hours
Observational data: associations, not effects.
Further findings
- No correlation overall between age, renal function, or sex
Original publication
Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial. Reg Anesth Pain Med. Published 6 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →